BIMEKIZUMAB EFFICACY IN MODERATE TO SEVERE PLAQUE PSORIASIS: IMPROVEMENTS IN FATIGUE OBSERVED IN TWO PHASE 3 STUDIES

被引：0
|
作者：
Gottlieb, Alice B. [1 ]
Augustin, Matthias [2 ]
Lambert, Jo [3 ]
Pinter, Andreas [4 ]
Savage, Laura J. [5 ]
Tsai, Tsen-Fang [6 ,7 ]
Foley, Peter [8 ]
Paul, Carle [9 ,10 ]
Warham, Rhys [11 ,12 ]
Lambert, Jeremy [1 ,13 ]
Wiegratz, Susanne [1 ,14 ]
Stahle, Mona [1 ,15 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[2] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
[3] Ghent Univ Hosp, Ghent, Belgium
[4] Univ Hosp Frankfurt, Frankfurt, Germany
[5] Leeds Teaching Hosp NHS Trust, Leeds, England
[6] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan
[7] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[8] Univ Melbourne, St Vincents Hosp Melbourne, Skin Hlth Inst, Carlton, Australia
[9] Toulouse Univ, Toulouse, France
[10] CHU, Toulouse, France
[11] Veramed, London, England
[12] UCB Pharm, Slough, England
[13] UCB Pharm, Colombes, France
[14] UCB Pharm, Monheim, Germany
[15] Karolinska Inst, Dept Med, Solna, Sweden
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-133
引用
收藏
页数：102
相关论文
共 50 条
  • [41] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Puig, Luis
    Lebwohl, Mark
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Gomez, Natalie Nunez
    Eyerich, Kilian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
  • [42] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the openlabel extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Eyerich, Kilian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
  • [43] Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
    Blauvelt, Andrew
    Tada, Yayoi
    Iversen, Lars
    Mrowietz, Ulrich
    Lebwohl, Mark
    Wang, Maggie
    Vanvoorden, Veerle
    Cullen, Eva
    Staelens, Fabienne
    Papp, Kim A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
  • [44] Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis
    Tan, Huaming
    Valdez, Hernan
    Griffiths, Chris E. M.
    Mrowietz, Ulrich
    Tallman, Anna
    Wolk, Robert
    Gordon, Kenneth
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (01) : 3 - 7
  • [45] Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
    Menter, M. Alan
    Papp, Kim A.
    Cather, Jennifer
    Leonardi, Craig
    Pariser, David M.
    Krueger, James G.
    Wohlrab, Johannes
    Amaya-Guerra, Mario
    Kaszuba, Andrzej
    Nadashkevich, Oleg
    Tsai, Tsen-Fang
    Gupta, Pankaj
    Tan, Huaming
    Valdez, Hernan
    Mallbris, Lotus
    Tatulych, Svitlana
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (05) : 568 - 580
  • [46] Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
    Alan Menter
    Jennifer C. Cather
    Michael Jarratt
    Xiangyi Meng
    Adriana Guana
    Judit Nyirady
    [J]. Dermatology and Therapy, 2016, 6 : 639 - 647
  • [47] Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
    Menter, A
    Gordon, K
    Carey, W
    Hamilton, T
    Glazer, S
    Caro, I
    Li, N
    Gulliver, W
    [J]. ARCHIVES OF DERMATOLOGY, 2005, 141 (01) : 31 - 38
  • [48] Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: Pooled subgroup analyses by patient age of 4 phase 3 clinical studies
    Warren, Richard
    Guettner, Achim
    Morita, Akimichi
    Gisondi, Paolo
    Cooper, Simon
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB186 - AB186
  • [49] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
    David Pariser
    Ellen Frankel
    Joel Schlessinger
    Yves Poulin
    Ronald Vender
    Richard G. Langley
    Xiangyi Meng
    Adriana Guana
    Judit Nyirady
    [J]. Dermatology and Therapy, 2018, 8 : 17 - 32
  • [50] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
    Pariser, David
    Frankel, Ellen
    Schlessinger, Joel
    Poulin, Yves
    Vender, Ronald
    Langley, Richard G.
    Meng, Xiangyi
    Guana, Adriana
    Nyirady, Judit
    [J]. DERMATOLOGY AND THERAPY, 2018, 8 (01) : 17 - 32
12345